Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Return on Sales (2016 - 2025)

Cardiff Oncology's Return on Sales history spans 15 years, with the latest figure at 29.69% for Q4 2025.

  • For Q4 2025, Return on Sales rose 4835.0% year-over-year to 29.69%; the TTM value through Dec 2025 reached 77.33%, down 1097.0%, while the annual FY2025 figure was 77.33%, 1087.0% down from the prior year.
  • Return on Sales for Q4 2025 was 29.69% at Cardiff Oncology, up from 93.82% in the prior quarter.
  • Across five years, Return on Sales topped out at 29.69% in Q4 2025 and bottomed at 149.65% in Q1 2022.
  • The 5-year median for Return on Sales is 79.71% (2021), against an average of 89.22%.
  • The largest annual shift saw Return on Sales skyrocketed 9639bps in 2024 before it crashed -7450bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 71.62% in 2021, then dropped by -2bps to 73.38% in 2022, then grew by 19bps to 59.77% in 2023, then tumbled by -31bps to 78.05% in 2024, then surged by 62bps to 29.69% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Return on Sales are 29.69% (Q4 2025), 93.82% (Q3 2025), and 115.22% (Q2 2025).